ALMS — Alumis Inc.

Is ALMS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Alumis Inc. (ALMS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $6.85. The rating moved from Strong Oversold to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Alumis Inc. (ALMS) sits in a high-uncertainty data environment with no recent EDGAR-level filings to evaluate core financial health or runway. Market context is risk-averse with defensive flows and muted volumes; sector themes show funding and IPO demand for digital-health/device issuers cooling while specialty pharma clinical wins and policy-driven pricing pressure create mixed competitive forces. Near-term performance will hinge on company-specific disclosures (cash runway, milestones, regulatory timetable) and any demonstrable commercial or clinical catalysts. Absent clearer financials or a discrete positive catalyst, expect trading to remain range-bound and sensitive to broader healthcare sentiment, funding conditions, and policy headlines.

Key factors

  • Very limited public disclosure and no recent EDGAR filings available for cross-checking financials or runway
  • Near-term market tone is risk-off with light volumes, reducing chances of meaningful upside absent company-specific catalysts
  • Sector thematic: cooling IPO window for digital-health & device offerings increases funding and sentiment pressure for smaller healthcare issuers
  • Policy/market pressure on drug pricing and payer negotiation (Medicare/IRA) increases potential pricing and access headwinds for healthcare-related businesses
  • Broader biotech/specialty pharma clinical wins and combo-therapy innovation create mixed competitive dynamics depending on Alumis's exact product exposure
  • Unknown cash runway and capital needs given lack of filings — funding risk is a central determinant of near-term valuation moves
  • Short-term safe-haven rotations and geopolitical noise are likely to keep trading range-bound until clearer catalysts emerge

Risks

  • Insufficient public financial reporting prevents confident assessment of revenue, cash burn, and debt profile
  • If Alumis has device or consumer-health exposure, an icy IPO/funding window could restrict capital access or push dilution
  • Regulatory/clinical execution risk (trial delays, regulatory review outcomes) could materially move valuation
  • Pricing and reimbursement pressure from Medicare negotiation or PBM dynamics could reduce addressable market or margins
  • Supply-chain disruptions or manufacturing constraints could delay product launches or increase costs
  • Market liquidity risk: low trading volumes can amplify volatility and make exits/dilution more punitive for current holders
  • Macro/geopolitical shocks or renewed risk-off moves could depress the stock independent of company fundamentals

See today's live rating, score and targets

Members see the live hourly rating for ALMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.